vs

Side-by-side financial comparison of Edwards Lifesciences (EW) and Sunrun Inc. (RUN). Click either name above to swap in a different company.

Edwards Lifesciences is the larger business by last-quarter revenue ($1.6B vs $1.2B, roughly 1.4× Sunrun Inc.). Edwards Lifesciences runs the higher net margin — 23.1% vs 8.9%, a 14.2% gap on every dollar of revenue. On growth, Sunrun Inc. posted the faster year-over-year revenue change (123.5% vs 16.7%). Over the past eight quarters, Sunrun Inc.'s revenue compounded faster (59.0% CAGR vs 9.7%).

Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring. It developed the Sapien transcatheter aortic heart valve made of cow tissue within a balloon-expandable, cobalt-chromium frame, deployed via catheter.

Sunrun Inc. is an American provider of photovoltaic systems and battery energy storage products, primarily for residential customers. The company was established in 2007 and is headquartered in San Francisco, California.

EW vs RUN — Head-to-Head

Bigger by revenue
EW
EW
1.4× larger
EW
$1.6B
$1.2B
RUN
Growing faster (revenue YoY)
RUN
RUN
+106.8% gap
RUN
123.5%
16.7%
EW
Higher net margin
EW
EW
14.2% more per $
EW
23.1%
8.9%
RUN
Faster 2-yr revenue CAGR
RUN
RUN
Annualised
RUN
59.0%
9.7%
EW

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
EW
EW
RUN
RUN
Revenue
$1.6B
$1.2B
Net Profit
$380.7M
$103.6M
Gross Margin
78.0%
Operating Margin
1.8%
8.4%
Net Margin
23.1%
8.9%
Revenue YoY
16.7%
123.5%
Net Profit YoY
6.8%
103.7%
EPS (diluted)
$0.66
$0.38

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EW
EW
RUN
RUN
Q1 26
$1.6B
Q4 25
$1.6B
$1.2B
Q3 25
$1.6B
$724.6M
Q2 25
$1.5B
$569.3M
Q1 25
$1.4B
$504.3M
Q4 24
$1.4B
$518.5M
Q3 24
$1.4B
$537.2M
Q2 24
$1.4B
$523.9M
Net Profit
EW
EW
RUN
RUN
Q1 26
$380.7M
Q4 25
$91.2M
$103.6M
Q3 25
$291.1M
$16.6M
Q2 25
$333.2M
$279.8M
Q1 25
$358.0M
$50.0M
Q4 24
$385.6M
$-2.8B
Q3 24
$3.1B
$-83.8M
Q2 24
$366.3M
$139.1M
Gross Margin
EW
EW
RUN
RUN
Q1 26
78.0%
Q4 25
78.1%
Q3 25
77.8%
Q2 25
77.5%
Q1 25
78.7%
Q4 24
78.9%
Q3 24
80.6%
Q2 24
79.9%
Operating Margin
EW
EW
RUN
RUN
Q1 26
1.8%
Q4 25
9.6%
8.4%
Q3 25
19.8%
0.5%
Q2 25
26.8%
-19.7%
Q1 25
27.9%
-22.8%
Q4 24
22.6%
-628.0%
Q3 24
25.9%
-23.8%
Q2 24
26.8%
-24.4%
Net Margin
EW
EW
RUN
RUN
Q1 26
23.1%
Q4 25
5.8%
8.9%
Q3 25
18.7%
2.3%
Q2 25
21.7%
49.1%
Q1 25
25.3%
9.9%
Q4 24
27.8%
-542.7%
Q3 24
226.7%
-15.6%
Q2 24
26.7%
26.5%
EPS (diluted)
EW
EW
RUN
RUN
Q1 26
$0.66
Q4 25
$0.16
$0.38
Q3 25
$0.50
$0.06
Q2 25
$0.56
$1.07
Q1 25
$0.61
$0.20
Q4 24
$0.65
$-12.59
Q3 24
$5.13
$-0.37
Q2 24
$0.61
$0.55

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EW
EW
RUN
RUN
Cash + ST InvestmentsLiquidity on hand
Total DebtLower is stronger
$14.7B
Stockholders' EquityBook value
$3.1B
Total Assets
$22.6B
Debt / EquityLower = less leverage
4.69×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EW
EW
RUN
RUN
Q1 26
Q4 25
$4.2B
Q3 25
$3.8B
Q2 25
$4.1B
Q1 25
$3.9B
Q4 24
$4.0B
Q3 24
$4.4B
Q2 24
$2.0B
Total Debt
EW
EW
RUN
RUN
Q1 26
Q4 25
$14.7B
Q3 25
$14.6B
Q2 25
$14.0B
Q1 25
$13.6B
Q4 24
$12.9B
Q3 24
$12.5B
Q2 24
$12.0B
Stockholders' Equity
EW
EW
RUN
RUN
Q1 26
Q4 25
$10.3B
$3.1B
Q3 25
$10.2B
$3.0B
Q2 25
$10.5B
$2.9B
Q1 25
$10.1B
$2.6B
Q4 24
$10.0B
$2.6B
Q3 24
$9.5B
$5.3B
Q2 24
$7.4B
$5.4B
Total Assets
EW
EW
RUN
RUN
Q1 26
Q4 25
$13.7B
$22.6B
Q3 25
$13.3B
$22.2B
Q2 25
$13.5B
$21.2B
Q1 25
$13.0B
$20.4B
Q4 24
$13.1B
$19.9B
Q3 24
$13.0B
$22.1B
Q2 24
$10.1B
$21.4B
Debt / Equity
EW
EW
RUN
RUN
Q1 26
Q4 25
4.69×
Q3 25
4.90×
Q2 25
4.80×
Q1 25
5.19×
Q4 24
5.05×
Q3 24
2.36×
Q2 24
2.23×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EW
EW
RUN
RUN
Operating Cash FlowLast quarter
$96.9M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
0.94×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EW
EW
RUN
RUN
Q1 26
Q4 25
$450.9M
$96.9M
Q3 25
$573.7M
$-121.5M
Q2 25
$290.2M
$-292.7M
Q1 25
$280.4M
$-104.2M
Q4 24
$-127.5M
$-258.4M
Q3 24
$351.8M
$-156.2M
Q2 24
$371.5M
$-208.5M
Free Cash Flow
EW
EW
RUN
RUN
Q1 26
Q4 25
$353.5M
Q3 25
$516.2M
Q2 25
$240.9M
Q1 25
$224.4M
Q4 24
$-177.3M
Q3 24
$299.9M
$-156.4M
Q2 24
$286.1M
FCF Margin
EW
EW
RUN
RUN
Q1 26
Q4 25
22.5%
Q3 25
33.2%
Q2 25
15.7%
Q1 25
15.9%
Q4 24
-12.8%
Q3 24
22.1%
-29.1%
Q2 24
20.9%
Capex Intensity
EW
EW
RUN
RUN
Q1 26
Q4 25
6.2%
Q3 25
3.7%
Q2 25
3.2%
Q1 25
4.0%
Q4 24
3.6%
Q3 24
3.8%
0.0%
Q2 24
6.2%
Cash Conversion
EW
EW
RUN
RUN
Q1 26
Q4 25
4.94×
0.94×
Q3 25
1.97×
-7.33×
Q2 25
0.87×
-1.05×
Q1 25
0.78×
-2.08×
Q4 24
-0.33×
Q3 24
0.11×
Q2 24
1.01×
-1.50×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EW
EW

Segment breakdown not available.

RUN
RUN

Products$692.3M60%
Customer Agreements$435.2M38%
Manufactured Product Other$56.7M5%
Incentives$31.3M3%

Related Comparisons